YUMANITY THERAPEUTICS
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s... disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.
YUMANITY THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.yumanity.com
Total Employee:
11+
Status:
Active
Contact:
(973) 271-6085
Email Addresses:
[email protected]
Total Funding:
137.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Mobile Non Scaleable Content Nginx Sitelinks Search Box
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Venture Round - Yumanity Therapeutics
Ikarian Capital
Ikarian Capital investment in Venture Round - Yumanity Therapeutics
Altium Capital
Altium Capital investment in Venture Round - Yumanity Therapeutics
Stonepine Capital
Stonepine Capital investment in Venture Round - Yumanity Therapeutics
Maven Investment Partners US
Maven Investment Partners US investment in Venture Round - Yumanity Therapeutics
Invus
Invus investment in Venture Round - Yumanity Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Venture Round - Yumanity Therapeutics
Redmile Group
Redmile Group investment in Series A - Yumanity Therapeutics
Alexandria Venture
Alexandria Venture investment in Series A - Yumanity Therapeutics
Dolby Family Ventures
Dolby Family Ventures investment in Series A - Yumanity Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-16 | Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants |
Official Site Inspections
http://www.yumanity.com Semrush global rank: 5.64 M Semrush visits lastest month: 1.49 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Yumanity Therapeutics"
Kineta (Reverse Merger With Yumanity Therapeutics)
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech …See details»
Yumanity Therapeutics Announces Definitive Agreements for
Jun 6, 2022 Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at …See details»
Yumanity's days as an independent biotech come to a close
Jun 6, 2022 Dive Brief: Yumanity Therapeutics, a Boston-based developer of brain drugs, announced Monday plans to offload its remaining research assets and enter into a reverse …See details»
Yumanity Therapeutics, Inc.
Yumanity moved YTX-7739 into a clinical trial in Parkinson's disease patients on the strength of the mice data, but its data drop received a frosty reception late last year. ... The statistics for …See details»
Yumanity Therapeutics Announces Strategic Research
Jun 24, 2020 Yumanity and Merck will collaborate to advance the two preclinical programs during the research term, after which Merck has the right to continue clinical development and …See details»
Yumanity Therapeutics Announces Strategic Research ... - Merck
Yumanity Therapeutics, a leader in the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that it has entered into a …See details»
Biotech Startup Yumanity Therapeutics Launched To Develop New...
Dec 16, 2014 Previously vice president of neurology discovery at Biogen Idec, an organization focused on discovery and early development of protein and small molecule drugs in neurology …See details»
Yumanity Therapeutics - VentureRadar
Feb 10, 2018 Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Formed in 2014 by renowned biotech industry leader, …See details»
Yumanity Therapeutics - Craft
Dec 19, 2022 Yumanity Therapeutics (formerly known as Proteostasis Therapeutics) is a biopharmaceutical company developing therapeutics to treat diseases caused by an …See details»
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance ...
Feb 17, 2022 Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its …See details»
Yumanity, Inc. Company Profile | Seattle, WA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Yumanity, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
Yumanity Therapeutics Announces Filing of Registration Statement …
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and …See details»
J&J pays $26M for neuroscience assets - Fierce Biotech
Jun 6, 2022 YTX-7739 spearheaded Yumanity’s advance in its early years, helping it raise more than $100 million and then join Nasdaq through a reverse merger with Proteostasis in 2020. …See details»
Yumanity Therapeutics Reports Full-Year 2021 Financial Results …
Mar 24, 2022 Yumanity is eligible to receive more than $500 million in future milestones and royalties under this research agreement. In January 2022, the U.S. Food and Drug …See details»
Yumanity Therapeutics Announces Study Demonstrating In Vivo
Apr 6, 2021 “As a science-driven organization that is dedicated to developing disease-modifying ... About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical …See details»
Yumanity Shares Update on Potential Treatment YTX-7739
Feb 16, 2021 Following these promising early findings, Yumanity launched a Phase 1 trial to assess the safety, tolerability, and pharmacological properties of YTX-7739 in a group of …See details»
Lumanity
Dec 7, 2023 The data landscape is complex and evolving rapidly. The expanding number of data types and sources, the advancement of technology-driven solutions, and the increasing …See details»
Yumanity Therapeutics Reports Third Quarter 2021 Financial …
Nov 15, 2021 Announced Successful Phase 1b trial for YTX-7739 in Parkinson’s disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable …See details»
Youmanity- Humanising Work and Transforming the Workplace
We are YOUmanity - a national organisational consulting firm. We are a passionate group of people with multi-disciplinary backgrounds, combining diverse thinking and lived experience to …See details»
Unity ID
Unity is the ultimate game development platform. Use Unity to build high-quality 3D and 2D games, deploy them across mobile, desktop, VR/AR, consoles or the Web, and connect with …See details»